Based on the evidence from preclinical and clinical studies, a hypothesis can be proposed that the impact of BTK inhibition on RA disease pathology may be more by altering B cell development affecting subsequent immune processes that are dependent on B cell differentiation than by directly affecting inflammatory activity. Here, BTK is linked to rheumatoid arthritis.